Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | IDH2 | P48735 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7805558 | 0.94 | IDH2 (0.61) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7807185 | 0.89 | CNR1 (0.62) | PFKFB3CNR1CA12CA1CA2 | |
| SCHEMBL7797518 | 0.88 | CNR1 (0.56) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7805075 | 0.88 | IDH2 (0.54) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7798880 | 0.86 | MAPT (0.55) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7806992 | 0.86 | CNR1 (0.58) | CNR1MAPTCA12CA1CA2 | |
| SCHEMBL7811717 | 0.86 | IDH2 (0.52) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7811207 | 0.86 | LMNA (0.55) | PFKFB3CNR1MAPTCA12CA1 | |
| SCHEMBL7805723 | 0.86 | CNR1 (0.58) | CNR1MAPTCA12CA1CA2 | |
| SCHEMBL8278220 | 0.86 | PGR (0.62) | PFKFB3MEN1KMT2AKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | PFKFB3 3583/4885CNR1 174/4885MAPT 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.